Icariin stimulates myeloid Leukemic cells differentiation by increasing smad4 protein abundance leading to the inhibition of myeloid Leukemic cell growth

Yixuan Cao

doi:10.54254/2753-8818/24/20231090

Article Information

Received: 29 November 2023

Published: 20 December 2023

DOI: https://doi.org/10.54254/2753-8818/24/20231090

Article Type: Research Article

Cite this article

Cao,Y. (2023). Icariin stimulates myeloid Leukemic cells differentiation by increasing smad4 protein abundance leading to the inhibition of myeloid Leukemic cell growth. Theoretical and Natural Science,24,25-32.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.24

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Shallis, R.M., et al. (2019) Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood reviews, 36: p. 70-87.

[2]Bispo, J.A.B., P.S. Pinheiro, and E.K. Kobetz. (2020) Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine, 10(6).

[3]Chien, L.-N., et al. (2023) Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015. Journal of the Formosan Medical Association, 122(6): p. 505-513.

[4]Jaramillo, S. and R.F. Schlenk. (2023) Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica, 108(2): p. 342-352.

[5]Zhao, J.C., et al. (2022) A review of FLT3 inhibitors in acute myeloid leukemia. Blood reviews, 52: p. 100905.

[6]Ishii, H. and S. Yano. (2022) New therapeutic strategies for adult acute myeloid leukemia. Cancers, 14(11): p. 2806.

[7]Babakhanlou, R. and F. Ravandi-Kashani. (2023) Non-intensive acute myeloid leukemia therapies for older patients. Expert review of hematology, 16(3): p. 171-180.

[8]Hanahan, D. (2022) Hallmarks of cancer: new dimensions. Cancer discovery, 12(1): p. 31-46.

[9]Yang, L., et al. (2006) Acute myelogenous leukemia–derived SMAD4 mutations target the protein to ubiquitin‐proteasome degradation. Human mutation, 27(9): p. 897-905.

[10]Imai, Y., et al. (2001) Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene, 20(1): p. 88-96.

[11]McCarthy, A.J. and R. Chetty, Smad4/DPC4. (2018) Journal of clinical pathology, 71(8): p. 661-664.

[12]Chang, H., et al.(2000) Smad5 is essential for left–right asymmetry in mice. Developmental biology, 219(1): p. 71-78.

[13]Pakravan, K., et al.(2022) SMAD4 contributes to chondrocyte and osteocyte development. Journal of Cellular and Molecular Medicine, 26(1): p. 1-15.

[14]Seyedi, Z., et al. (2023) Icariin: A promising natural product in biomedicine and tissue engineering. Journal of Functional Biomaterials, 14(1): p. 44.

[15]Xia, S.-l., et al.(2023) Icariin promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells in patients with osteoporosis and T2DM by upregulating GLI-1. Journal of Orthopaedic Surgery and Research, 18(1): p. 500.

[16]Xie, D., et al.(2023) Icariin promotes osteogenic differentiation by upregulating alpha-enolase expression. Biochemistry and Biophysics Reports, 34: p. 101471.

[17]Zhang, X., et al. (2018) Local icariin application enhanced periodontal tissue regeneration and relieved local inflammation in a minipig model of periodontitis. International Journal of Oral Science, 10(2): p. 19.

[18]Skopek, R., et al. (2023) Choosing the right cell line for acute myeloid leukemia (AML) research. International Journal of Molecular Sciences, 24(6): p. 5377.